Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France
During the last decade, oral bisphosphonates (BP) became the most widely prescribed pharmacologic class for post-menopausal osteoporosis. However, many surveys revealed the important issue of poor persistence ...